2 completed. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
Follow LY3321367: new trials by email Literature Review of LY3321367 trials Research Report on LY3321367
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors LY3321367, LY3300054 - Solid Tumor | Phase 1 | Completed | Eli Lilly and Company | 209 | 2017-04-12 | 2023-10-17 |
| A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors LY3300054, Ramucirumab, Abemaciclib - Solid Tumor, Microsatellite Instability-High (MSI-H) Solid Tumors | Phase 1 | Completed | Eli Lilly and Company | 164 | 2016-06-29 | 2024-09-27 |
Breast Neoplasms (1) · Melanoma (1) · Pancreatic Neoplasms (1)
South Korea (2) · Spain (2) · United States (2) · Belgium (1) · Canada (1) · France (1) · Japan (1) · Taiwan (1)
PMID 33229456, PMID 33514524, PMID 34465599
2016 (2)